The conversation discusses using ZIX, a combination of Zinc Sulfate and Vitamin B6, for hair loss. The user is considering liquid forms for better absorption and scalp health.
The conversation discusses whether adding latanoprost to finasteride and minoxidil is more effective for hair loss than using finasteride and minoxidil alone. Users criticize the lack of comparison to the established combination of finasteride and minoxidil.
A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The conversation is about hair loss treatment using topical minoxidil, finasteride, and arginine, showing noticeable progress in one month. The user suggests adding arginine serum for better results.
L'Oreal Serioxyl and Garnier Fructus Stemoxydine are compared for effectiveness in hair loss treatment. The user considers switching from Serioxyl to the cheaper Garnier Fructus but is unsure about its effectiveness and stemoxydine percentage.
Jericho1017 shared their hair regrowth results after nearly 3 years using 1mg finasteride and 10,000mcg biotin daily, with noticeable improvement after 1.5 years and no significant side effects except for watery semen. Some users suggested adding minoxidil and microneedling to improve results, but Jericho1017 is currently content with their progress and not looking to add more treatments.
A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.
Landon Donovan recently had a hair transplant, leading to noticeable changes in his appearance. The conversation revolves around his confidence and reactions to his new look.
The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.
The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.
A user shared their 20-week progress using oral finasteride (1mg) and oral minoxidil (3.3mg) for hair loss, noting significant improvement in hair thickness and coverage. Another user complimented the progress.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
The user experienced significant hair regrowth using oral finasteride (1 mg) and oral minoxidil (2.5 mg) daily, with minimal side effects. They also use testosterone to balance any libido effects from finasteride.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
A 22-year-old male shared his positive experience using 1 mg finasteride daily for two years, noting significant hair thickening and texture improvement without side effects. Other users discussed their own hair loss treatments, including finasteride and minoxidil, and shared encouragement and advice.
A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.
User shared progress pictures showing significant hair regrowth using a compounded solution of Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Latanoprost 0.005%. They reported no side effects and are satisfied with the results.
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.